CRISPR Therapeutics AG
corporate_fare Company Profile
CRISPR Therapeutics AG (NASDAQ:CRSP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for CRSP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for CRSP spans 10-Q, 8-K, DEFA14A, DEF 14A.
Recent high-impact activity:
- CTX310 Cuts Triglycerides 63% at Day 30, Beating Analyst Expectations
- CTX310 Cuts Triglycerides 63% at Day 30 in Severe Hypertriglyceridemia
- CRISPR Q3: Net Loss $111.4M, $2.28B Cash, 24-Month Runway Confirmed
- CRISPR Q3: CASGEVY Revenue $99M, Up 30% QoQ; CTX310 Wins Two RMAT Designations
- CRISPR Therapeutics Posts $12.7M in Q3 Revenue
Financial Snapshot
Short Interest & Short Volume
13.09 days to coverFINRA reported short interest of 17,189,067 shares in CRSP as of the October 30, 2026 settlement, a 4.5% increase from the prior period — about 13.1 days to cover at its recent average daily volume. On November 20, 2026, 59.6% of CRSP volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for CRSP, detected from its recent SEC filings · based on capital-structure filings through 2026-06-04.
New Equity Incentive Plan Approved · Capital Band Increase Authorized
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →